The diabetes and weight loss drug semaglutide reversed liver scarring and inflammation. It’s among several drugs in the works for the condition MASH.

A phase 3 trial shows that once-weekly semaglutide significantly improves liver histology in patients with metabolic ...

The proprietary Self-Emulsifying Drug Delivery System (SEDDS) formulation in form of orally dispersible films allows absorption of sublingually administrated peptides such as GLP-1 (Semaglutide ...

We want you to take advantage of everything Clinical Advisor has to offer. To view unlimited content, log in or register for free.

Allen Baharaff, President and CEO of Galmed Pharmaceuticals commented: "We signed a term sheet that provides Galmed the opportunity to license, develop and commercialize a novel Semaglutide ...

The proprietary Self-Emulsifying Drug Delivery System (SEDDS) formulation in form of orally dispersible films allows absorption of sublingually administrated peptides such as GLP-1 (Semaglutide, ...

More than half of adults with MASH receiving semaglutide had resolution of steatohepatitis at 72 weeks. A reduction in liver fibrosis stage was observed among 36.8% of the semaglutide group.

Findings showed a 13.6% reduction in body weight in the semaglutide 25mg group compared with a 2.2% reduction in the placebo group. The Food and Drug Administration (FDA) has accepted for review ...